Short bowel syndrome (SBS) is an intestinal failure resulting from an inadequate length of intestine following intestinal resection. Intestinal failure refers to a condition that results in inadequate digestion or absorption of nutrients or both, so that an individual becomes malnourished and requires specialized medical and nutritional support.\(^1\)

The prevalence of SBS is 3-4 per million.\(^1\) It occurs in about 15% of adult patients who undergo intestinal resection, with 3/4\(^{th}\) of these cases resulting from massive intestinal resection and 1/4\(^{th}\) from multiple sequential resections.\(^2\) About 70% of patients in whom SBS develops are discharged from the hospital and a similar percentage remain alive a year later.\(^1\) This improved survival rate has been achieved primarily by the ability to deliver long-term nutritional support.

Etiology and Pathophysiology

Several conditions requiring intestinal resection lead to SBS. In a reported series of 210 cases, these conditions included postoperative 52 (25%), irradiation/cancer 51 (24%), mesenteric vascular disease 46 (22%), Crohn’s disease 34 (16%) and other benign causes 27 (13%).\(^3\) The manifestations of SBS are due to:

1. Loss of absorptive surface area
2. Loss of site-specific transport processes
3. Loss of site-specific endocrine cells and gastrointestinal (GI) hormones
4. Loss of ileocecal valve

The major consequence of extensive intestinal resection is loss of absorptive surface area, which results in malabsorption of macro and micronutrients, electrolytes and water.\(^5\) Most macronutrients are absorbed in the proximal 100–150 cm of intestine.\(^6\) Specific micronutrients are absorbed from specific areas of small intestine. Intestinal remnant length is the primary determinant of outcome in patients with SBS. Resection of up to half of small intestine is generally well tolerated. SBS is likely to develop in patients with loss of two-
thirds length of small intestine. Permanent total PN (TPN) support is likely to be needed in patients with less than 120 cm of intestine without colon in continuity and less than 60 cm with colonic continuity.[7] Besides, malabsorption of macro and micronutrients with a loss of intestinal absorptive surface area results in water and electrolyte malabsorption, which manifests as voluminous diarrhea, hypovolemia, hyponatremia and hypokalemia.

The absorption of some compounds is restricted to certain areas of small intestine. Iron, phosphorus and water soluble vitamins are predominantly absorbed in proximal small intestine. As most patients with SBS have intact duodenum and proximal jejunum, deficiencies of these entities are rare but tend to develop calcium and magnesium deficiency.[8] Having lost part or whole of the ileum, vitamin B12 and bile salt malabsorption also develops. Even hormones in the GI mucosa are distributed in a site specific manner. Gastrin, cholecystokinin, secretin, gastric inhibitory polypeptide and motilin are produced by endocrine cells in proximal gastrointestinal tract (GIT). In SBS, the status of these hormones remains intact. Glucagon-like peptide (GLP) 1 and 2, neurotensin, and peptide YY are produced in ileum and proximal colon. In SBS, deficiency of these hormones is common and this results in rapid gastric emptying, shortened intestinal transit and hypergastrinemia.[9,10] The presence of ileocecal junction improves the functional capacity of intestinal remnant.[11] Although previously this had been attributed to a barrier function and transit prolonging property of ileocecal valve, this advantage may actually be related to the specialized property of the terminal ileum itself.

**INTESTINAL ADAPTATION**

The small intestine is able to adapt to compensate for the reduction in absorptive surface area caused by intestinal resection. This process occurs in the first couple of years following resection.[12] This adaptive response results from changes in the intestinal structure, motility and function. Structural adaptation following intestinal resection involves all the layers of the intestine.[13] The process is characterized by crypt cell proliferation, lengthening of the villi, increase in the ratio of the crypts to villi, increase in microvilli along the epithelial surface and an overall increase in the mucosal weight. The thickness and length of muscle layers increase as a result of hyperplasia.

Intestinal motor activity is also altered by intestinal resection.[14] Motor adaptation seems to be more prominent in the jejunum than in the ileum. There is disrupted motor activity in the first few months after resection followed by adaptation. Studies demonstrate a shorter duration of migrating motor complex cycle and fed pattern after resection.[15] Functional adaptation results in improved absorption by individual enterocytes.[1] This process is facilitated by structural and motor adaptation which results in prolonged intestinal transit time.

The mechanism of intestinal adaptation is not entirely understood. The degree of intestinal adaptation is related to the extent and site of intestinal resection.[15] Adaptation is greater with extensive intestinal resection and ileum has a greater adaptive capacity than jejunum. Factors which influence intestinal adaptation include GI regulatory peptides, growth factors, hormones, cytokines, and tissue factors which include immunity, blood flow and neural influences.

**MEDICAL MANAGEMENT**

The early management of a patient with SBS is that of a critically ill surgical patient who has recently undergone intestinal resection and other concomitant procedures. Thus, control of sepsis, maintenance of fluid and electrolyte balance and initiation of nutritional support are important in the early management of these patients. For patients who have survived this early phase, the primary goals of management are to maintain adequate nutritional status and prevent development of complications related to both underlying pathophysiology and nutritional therapy.

**Maintenance of nutritional status**

This is the primary objective in the management of SBS. Fluid and electrolyte losses from the GIT may be great in the early postoperative period and must be monitored and replaced. TPN will be required in the early postoperative period and enteral nutrition should be initiated as soon as possible.

Patients with limited ileal resection (less than 100 cm) with or without right hemicolectomy can resume intake of solid food in late postoperative phase. These patients may develop diarrhea or steatorrhea with consumption of a regular diet due to fat malabsorption, which in turn can lead to deficiencies of fat soluble vitamins, vitamin B12, calcium and magnesium. The deficiencies of these nutrients should be looked for and these nutrients should be supplemented if needed. Maintenance of nutritional status becomes all the more important in the setting of diarrhea, which is quite common in SBS and may be due to gastric acid hypersecretion, rapid intestinal transit time and fat malabsorption. H2 blockers, proton pump inhibitors (PPI), antidiarrheals, cholestyramine and octreotide have all been used to control diarrhea. Octreotide acts by slowing intestinal transit and increasing sodium and water reabsorption,[16] but carries potential risk of decreasing splanchnic protein synthesis, thereby inhibiting intestinal adaptation and also a risk of cholelithiasis. These medications should be taken...
one hour before meals and their effect on diarrheal volume should be evaluated before they are recommended for long-term treatment.

Glucose polymer-based oral rehydration salts (ORS) are recommended for patients to improve hydration and thereby reduce TPN requirements. Glucose and sodium are absorbed through the same active transport mechanisms and stimulate the absorption of each other. In addition, glucose promotes sodium and water absorption by means of solvent drag.

**Dietary management and special diets**

Patients with SBS should be encouraged to eat substantially more than usual (a hyperphagic diet) to compensate malabsorption. Patients should be encouraged to eat small portions throughout the day rather than at defined meal times. Those with colonic continuity should be provided with a high complex carbohydrate diet containing starch, non-starch polysaccharides and soluble fibers. These food stuffs which are typically not absorbed by human small intestine get fermented by colonic bacteria into butyrate, acetate and propionate. Butyrate is the preferred fuel for colocytes. Studies have indicated that up to 525 to 1170 kcal per day can be absorbed from an intact colon from fermentation of unabsorbed carbohydrates and soluble fibers. The amount of energy absorbed is proportional to the length of residual colon and may increase as a part of adaptive response to enterectomy.

**Treatment of steatorrhea associated with ileal resection**

Fat maldigestion due to bile salt malabsorption occurs when more than 100 cm of terminal ileum has been resected. Various therapeutic options have been suggested for the treatment of the resulting steatorrhea. Use of bile salt replacement therapy with ox bile or a synthetic conjugated bile acid (cholesarcosine) has been reported. The bile acid sequestering agent cholestyramine may be useful in decreasing bile salt related diarrhea in patients with less than 100 cm of terminal ileum loss, but may worsen steatorrhea in those patients who have undergone a more significant resection, because of its binding with dietary lipid. Also cholestyramine interferes with absorption of many medications. These patients may be put on low-fat high-carbohydrate diet. Low fat may decrease steatorrhea, but it also results in decreased energy intake which may worsen patients energy balance. However, a high fat intake is associated with malabsorption of divalent cations, delayed gastric emptying, early satiety and increased water loss from colon. Since medium chain triglycerides (MCT) are absorbed in colon, dietary supplementation with MCT may lead to increased energy consumption. Limitations of MCT include the fact that they do not provide essential fatty acids (FAs) and can cause nausea, vomiting and ketosis.

Another important aspect of dietary management is to provide a diet that will maximize intestinal adaptive response. Provision of fat and dietary fibers may be particularly important in this regard. Long and short chain FA appear to have a greater trophic effect on the intestine than medium chain FA do. Although these nutrients directly stimulate intestinal adaptation, they also bring about intestinal adaptation through endocrine and paracrine effects.

Pharmacologic therapy for SBS is a rapidly expanding area of investigation. Recent evidence suggests that provision of appropriate diet, nutritional supplements such as glutamine and growth factors such as growth hormone improves intestinal absorption and perhaps modifies the adaptive response in patients with established SBS. Currently GLP-2 appear to have the most promising results.

**Home parenteral nutrition**

Home parenteral nutrition is an option for patients who require long-term TPN. To prepare the patient for home TPN, the regime should be compressed gradually in 2 to 4 h daily increments so that the total volume can be infused over a 10–12-h period, typically over night. The TPN infusion is generally tapered off over a 30–60-min period to avoid hypoglycemia. Additional fluid allowances may be needed for patients with a permanent jejunostomy. The TPN solutions should be infused into a central vein such as superior or inferior venacava through a tunneled catheter to decrease the risks of infection and thrombosis.

**Prevention of complications**

Complications in SBS could be related to either the underlying pathology or the nutritional therapy. Among patients who require long-term TPN for survival, sepsis and liver disease related to TPN are important factors governing morbidity and mortality. The incidence of sepsis varies from 0.1 to 0.3 episodes per patient per year of TPN. Sepsis may be associated with catheter thrombosis. In cases with catheter-related sepsis an attempt at line sterilization before removal is appropriate when infections are caused by coagulase-negative staphylococci and gram-negative bacteria.

End-stage liver disease develops in about 15% of patients on long-term TPN and is associated with a survival time of about 1 year without liver transplantation. The etiology of TPN-associated liver disease is not completely understood and seems to be multifactorial. This is reversible in initial stages, but ultimately leads to severe steatosis, cholestasis and cirrhosis. The liver function tests (LFTs) of patients on long-term TPN should be monitored regularly and patients with abnormal LFT should undergo ultrasound evaluation of gall bladder and bile ducts and should have a liver biopsy performed, as appropriate. TPN-induced liver disease can be
minimized by providing high calories enterally, avoiding overfeeding, using mixed ‘fuels’ (less than 30% fat), preventing specific nutrient deficiencies, treating bacterial growth and preventing recurrent sepsis. Ursodeoxycholic acid administration may be beneficial.

Metabolic complications in SBS include hypocalcemia, hypomagnesemia and fat soluble vitamin deficiencies. A specific problem is D-lactic acidosis, which results from bacterial fermentation of unabsorbed nutrients particularly simple sugars. The diagnosis is suggested by unexplained metabolic acidosis and associated neurological symptoms. Treatment includes minimizing overall caloric intake or instituting a low carbohydrate diet. Administration of intestinal antibiotics may be appropriate.

Cholelithiasis occurs in 30–40% of patients with intestinal insufficiency. Factors that predispose to gall stone formation include altered hepatic bile metabolism and secretion, gall bladder stasis and malabsorption of bile acids. Long-term TPN is an important contributing factor. The risk for cholelithiasis increases significantly if less than 120 cm of intestine remains after resection, if the terminal ileum has been resected and if the patient is on TPN. The incidence of cholelithiasis can be minimized by providing enteral nutrition whenever feasible. Cholelithiasis among patients on TPN can be prevented by intermittent cholecystokinin injections and administration of intravenous lipids both of which prevents gall bladder stasis. Several authors recommend prophylactic cholecystectomy in these patients when laparotomy is undertaken for other reasons.

Calcium oxalate stones are formed as a result of increased oxalate absorption from the colon. Nephrolithiasis is more common among patients with an intact colon and can be prevented by maintaining the patient on a diet low in oxalate, minimizing intra luminal fat, supplementing diet with calcium orally and maintaining a high urinary volume. Cholestyramine which binds to oxalic acid in colon is another potential agent, which can be used for treatment.

Gastric hypersecretion can be a serious problem in SBS and is due to parietal cell hyperplasia and hypergastrinemia. In addition to malabsorption and diarrhea, gastric hypersecretion can cause or flare up peptic ulcer disease. H2 receptor antagonists or PPI can be tried with good results. Few intractable cases may need surgical intervention. A highly selective vagotomy may be the most desirable procedure if feasible.

Bacterial overgrowth can occur among patients with SBS. Causes include impaired intestinal motility, stasis and achlorhydria. Bacterial overgrowth results in impaired bile absorption, vitamin B12 deficiency and diarrhea and may require long-term administration of intestinal antibiotics. Various drugs are used to treat or control the complications of SBS and are outlined in Table 1.

SURGICAL MANAGEMENT

The primary goal of surgical therapy for SBS is to increase the intestinal absorptive capacity and can be achieved by:

Preserving the existing intestine

An abdominal reoperation is required in about half of the patients with SBS. Intestinal problems are the most common indications. The strategy in such a reoperation should be to avoid resection and preserve the existing length of intestinal remnant. The procedures that can be employed as alternatives to resection in such instances include (1) stricturoplasty for benign strictures and (2) serosal patching for certain strictures and chronic perforations. When resection becomes unavoidable, an end to end anastomosis is preferred to prevent blind loops and maximize functional length of intestine.

Improving the intestinal function

The functioning of existing intestine can be enhanced by improving the motility and slowing the intestinal transit.

Improving the intestinal motility

The motility of intestinal remnant in SBS deteriorates

| Complication                  | Drugs                                      | Comments                                                      |
|-------------------------------|--------------------------------------------|----------------------------------------------------------------|
| Protein energy malnutrition   | Cholestyramine                             | Little evidence for use as bile acid replacement therapy       |
| Diarrhea                      | Loperamide 2–8 mg; occasionally codeine phosphate 30–60 mg | Management is same as in patients with jejunostomy             |
| Gastric acid hypersecretion   | Proton pump inhibitor (omeprazole, pantoprazole or rabeprazole) | Usually continued up to six months                             |
| Gall stones                   | IV amino acids infusion, Inj. cholecystokinin, NSAIDs, ursodeoxycholic acid, metronidazole | Therapy aims in preventing the formation of biliary sludge     |
| Hypomagnesemia                | Cap. Magnesium oxide, 1-α hydroxyl-cholecalciferol | Rehydration to correct secondary hyperaldosteronism is important |
over a period of time due to dilatation of intestine. This dilatation could be due to chronic unresolved obstruction or intestinal adaptation. All attempts should be made to relieve any obstruction. As the dilated segment cannot generate sufficient intraluminal pressures during peristalsis, it should be narrowed. This procedure is called “tapering enteroplasty”. The preferred methods of tapering enteroplasty are (1) simple imbrication of redundant bowel and (2) longitudinal transection and removal of part of the circumference of intestine along the antimesenteric border. Tapering enteroplasty does improve intestinal function in patients with SBS.\textsuperscript{[31]}

**Prolong intestinal transit**

Various methods are described as below:

1. **Reversed intestinal segments:** Reversing the segments of intestine to slow intestinal transit is the most extensively reported surgical procedure. The antiperistaltic segment functions by inducing retrograde peristalsis distally and disrupting the motility of the proximal intestine. In addition, disruption of the intrinsic nerve plexus slows myoelectric activity in the distal segment. Reversed segment also alters the hormonal milieu. The ideal antiperistaltic segment slows transit without causing complete obstruction. Technically the optimal length of the reversed segment should be 10 cm or less among adults and 3 cm or less among children. The reversed segment should be created as distal as feasible. Care must be taken to avoid complete rotation of the mesentery to avoid ischemia. Studies have shown that clinical improvement with slowed intestinal transit can be seen in 80% of patients treated by reversed intestinal segments.\textsuperscript{[32]} The potential complications are transient obstructive symptoms and anastomotic leak.

2. **Intestinal valves:** Several different techniques for creating intestinal valves and sphincters have been described. Valves or sphincters may be created by external constriction of the intestine, segmental denervation and intussusception of intestinal segments to increase intraluminal pressure; with the latter being the most frequently employed procedure.\textsuperscript{[33]} Intussuscepted valves should be 2 cm in length if prolapsed retrograde and 6 cm if prolapsed antegrade. Valves act by creating a partial obstruction disrupting the normal motor pattern of small intestine and preventing retrograde reflux of colonic contents.\textsuperscript{[33]} Potential complications include valve necrosis, complete obstruction and intussusception.

3. **Colonic transposition:** Interposing a colonic segment in the small intestinal remnant in either isoperistaltic or antiperistaltic fashion retards intestinal transit. Interposed colonic segment absorbs water, electrolytes and nutrients in addition to their effect on intestinal transit. A study has reported a success rate of 50% with colonic transposition among patients with SBS and also suggests that isoperistaltic transposition may be better than antiperistaltic.\textsuperscript{[33]}

Also intestinal pouches, recirculating loops and intestinal pacing in retrograde fashion have all been theoretically suggested to prolong intestinal transit time. However, in practice the results have been disappointing.

**Increasing absorptive surface area of intestine**

The intestinal absorptive area can be increased by:

**Intestinal tapering and lengthening procedures**

- Bianchi’s procedure
- Serial transverse enteroplasty procedure (STEP)

In both the procedures, the dilated segments of intestine are tapered, redundant intestine is preserved and restored into continuity for additional length.

Bianchi’s procedure is performed by transecting distal to the dilated segment to be tapered.\textsuperscript{[34]} Dissection is performed longitudinally for about 5 cm on the mesenteric edge of the bowel between the terminal branching vessels to create a space that permits longitudinal division of the bowel with a stapler. This procedure is repeated until the desired length is achieved. The two longitudinal segments can then be anastomosed end to end to halve the diameter and double the length of the segment.

Serial transverse enteroplasty procedure (STEP) involves serial transverse applications of a linear stapler from alternate directions to divide the bowel perpendicular to the long axis of the intestine.\textsuperscript{[35]} The length and spacing of the transverse division are determined by the diameter of the intestine. The net result will be an increase in the length and reduction in the diameter of the intestine. This procedure is less complicated than Bianchi procedure.

Intestinal lengthening has now been reported in more than 100 patients. Improvements in absorptive capacity and nutritional status have been reported in about 90% of these patients in the short term. Complications like a prolonged initial ileus, necrosis of divided segments, anastomotic leak and obstruction have been observed in 20% of patients.\textsuperscript{[36]} Although short-term results are encouraging, emerging long-term results suggest that only about half of the patients undergoing intestinal lengthening procedures have a sustained benefit for up to 10 years. The limitations of these procedures are that they can be applied in only a select group of patients. The patient should have a favorable vascular anatomy for Bianchi’s procedure. The patients selected should have a dilated intestinal segment with features of bacterial overgrowth or other signs of malabsorption.
Intestinal transplantation

Currently intestinal transplantation is being applied mainly as rescue therapy for patients with life-threatening complications of intestinal failure.

Types

- Isolated intestinal transplantation
- Combined liver and intestinal transplantation

Indications

- Life threatening complications of intestinal failure, most commonly TPN induced liver disease
- Irreversible permanent TPN requirement along with episodes of sepsis
- Irreversible permanent TPN requirement with loss of venous access

Outcome

Data from intestinal transplant registry (ITR) published in 2003 reveal that 959 transplants have been performed worldwide in 923 patients. Isolated intestinal transplant was performed 433 times and combined liver and intestinal transplant was performed 556 times. Four hundred and eighty four patients of 923 reported in ITR who underwent either of the procedures remained alive. This report suggests that graft and patient survival have steadily improved over time. Graft rejection rates were 57% for intestinal grafts, 30% for combined intestine and liver grafts and 48% for multivisceral grafts.[37]

The increasing experience and improved outcome of intestinal transplantation support the clinical use of this treatment modality. The benefits outweigh the potential morbidity and the procedure is potentially applicable to a greater number of patients with SBS.

FUTURE THERAPY

Research has revealed that administration of glucagon-like peptide 2 (GLP-2) to patients following major small bowel resection improves intestinal adaptation and nutrient absorption. Teduglutide, an enzyme-resistant GLP-2 analog shows a promise in preventing intestinal injury, restoring mucosal integrity, and enhancing intestinal absorptive function. Data from ongoing clinical trials indicate that teduglutide may have the ability to enhance intestinal absorptive capacity in patients with SBS. Further studies and the completion of phase III trials are necessary to determine the appropriate dosage and length of treatment for these patients to gain optimal therapeutic benefit from this drug.[38]

References

1. DiBaise JK, Young RJ, Vanderhoof JA. Intestinal rehabilitation and the short bowel syndrome. Part 1. Am J Gastroenterol 2004;99:1386-95.
2. Thompson JS. Comparison of massive vs. repeated resection leading to the short bowel syndrome. J Gastrointest Surg 2000;4:101-4.
3. Messing B, Crenn P, Beau P, Bourtouzi-MRC, Ramaud JC, Matuchansky C. Long-term survival and parenteral nutritional dependence in adult patients with the short bowel syndrome. Gastroenterology 1999;117:1043-50.
4. Thompson JS, DiBaise JK, Iver KR, Yeats M, Sudan DL. Postoperative short bowel syndrome. J Am Coll Surg 2005;201:85-9.
5. Andersson H, Rosaesu I, Brummer RJ, Fasth S, Hultén L, Magnusson O, Strauss B. Nutritional and metabolic consequences of extensive bowel resection. Dig Dis 1986;4:193-202.
6. Borgstrom B, Dahlqvist A, Lundh G, Sjovall J. Studies of intestinal digestion and absorption in the human. J Clin Invest 1957;36:1521-36.
7. Carbonnel F, Cosnes J, Chevret S, Beauregard L, Ngö Y, Malafosse M, et al. The role of anatomic factors in nutritional autonomy after extensive small bowel resection. J Parenter Enteral Nutr 1996;20:275-80.
8. Hessov I, Andersson H, Isaksson B. Effects of a low fat diet on mineral absorption in small bowel disease. Scand J Gastroenterol 1983;18:551-4.
9. Nightingale JM, Kamm MA, van der Sijp JR, Morris GP, Walker ER, Mather SJ, et al. Disturbed gastric emptying in the short bowel syndrome. Evidence for a ‘colonic brake’. Gut 1993;34:1171-6.
10. Williams NS, Evans P, King RF. Gastric acid secretion and gastrin production in the short bowel syndrome. Gut 1985;26:914-9.
11. Cosnes J, Gendre JP, Le Quintric Y. Role of the ileocecal valve and site of intestinal resection in malabsorption after extensive small bowel resection. Digestion 1978;18:329-36.
12. Jeppesen PE. Clinical significance of GLP-2 in short bowel syndrome. J Nutr 2003;133:3721-4.
13. Wilmore DW, Byrne TA, Persinger RL. Short bowel syndrome: New therapeutic approaches. Curr Probl Surg 1997;34:389-444.
14. Thompson JS, Quingley EM, Adrian TE. Factors affecting outcome following proximal and distal intestinal resection in the dog: An examination of the relative roles of mucosal adaptation, motility, luminal factors and, enteric peptides. Dig Dis Sci 1999;44:63-74.
15. Schmidt T, Pfeiffer A, Hackelsberger N, Widmer R, Meisel C, Kaess H. Effect of intestinal resection on human small bowel motility. Gut 1996;38:859-63.
16. Niv Y, Charash B, Sperber AD, Oren M. Effect of octreotide on gastrostomy, duodenostomy, and choledochojstomy effluents: A physiological study of fluid and electrolyte balance. Am J Gastroenterol 1997;92:2107-11.
17. Bond JH, Currier BE, Buchwald H, Levitt MD. Colonic conservation of malabsorbed carbohydrate. Gastroenterology 1980;78:444-7.
18. Little KH, Schiller RL, Bilhartz LE, Fordtran JS. Treatment of severe steatorrhea with ox bile in an ileectomy patient with residual colon. Dig Dis Sci 1992;37:929-33.
19. Hoffman AF, Polev JR. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology 1972;62:918-34.
20. Woolf GM, Miller C, Kurian R, Jeejeebhooy KN. Diet for patients with a short bowel: High fat or high carbohydrate? Gastroenterology 1983;84:823-8.
21. Jeppesen PB, Mortensen PB. The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. Gut 1998;43:478-83.
Management of short bowel syndrome

22. DiBaise JK, Young RJ, Vanderhoof JA. Intestinal rehabilitation and short bowel syndrome: Part 2. Am J Gastroenterol 2004;99:1823-32.
23. Wilmore DW, Lacey JM, Soultanakis RP, Bosch RL, Byrne TA. Factors predicting a successful outcome after pharmacologic bowel compensation. Ann Surg 1997;226:288-93.
24. Jeppesen PB. Glucagon-like peptide-2: Update of the recent clinical trails. Gastroenterology 2006;130(2 Suppl 1): S127-31.
25. Buchman AL, Moukarzel A, Goodson B, Herzog F, Pollack P, Reyen L, et al. Catheter-related infections associated with home parenteral nutrition and predictive factors for the need for catheter removal in their treatment. J PEN J Parenter Enteral Nutr 1994;18:297-302.
26. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000;132:525-32.
27. Thompson JS. The role of prophylactic cholecystectomy in the short bowel syndrome. Arch Surg 1996;131:556-60.
28. Nightingale JM, Lennard-Jones JE, Gertner DJ, Wood SR, Bartram CI. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones but does not change high prevalence of gall stones in patients with a short bowel. Gut 1992;33:1493-7.
29. Thompson JS, Langnas AN. Surgical approaches to improving intestinal function in the short bowel syndrome. Arch Surg 1999;134:706-11.
30. Thompson JS. Strategies for preserving intestinal length in short bowel syndrome. Dis Colon Rectum 1987;30:208-13.
31. Thompson JS, Langnas AN, Pinch LW, Kaufman S, Quigley EM, Vanderhoof JA. Surgical approach to short bowel syndrome. Experience in a population of 160 patients. Ann Surg 1995;222:600-7.
32. Thompson JS. Surgical approach to the short bowel syndrome: Procedures to slow intestinal transit. Eur J Pediatr Surg 1999;9:263-6.
33. Panis Y, Messing B, Rivet P, Coffin B, Hautefeuille P, Matuchansky C, et al. Segment reversal of the small bowel as an alternative to intestinal transplantation in patients with short bowel syndrome. Ann Surg 1997;225:401-7.
34. Bianchi A. Longitudinal intestinal lengthening and tailoring: Results in 20 children. J R Soc Med 1997;90:429-32.
35. Kim HB, Fauza D, Garza J, Oh JF, Nurko S, Jaksic T. Serial transverse enteroplasty (STEP): A novel bowel lengthening procedure. J Pediatr Surg 2003;38:425-9.
36. Thompson JS, Pinch LW, Young R, Vanderhoof JA. Long term outcome of intestinal lengthening. Transplant Proc 2000;32:1242-3.
37. Grant D, Abu-Elmagd K, Reyes J, Tzakis A, Langnas A, Fishbein T, et al. 2003 report of the intestine transplant registry: A new era has dawned. Ann Surg 2005;241:607-13.
38. Ferrone M, Scapolio JS. Teduglutide for the treatment of short bowel syndrome. Ann Pharmacother 2006;40:1105-9.

Source of Support: Nil, Conflict of Interest: None declared.

SJG is now in PubMed